A-867744 - CAS 1000279-69-5
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
A-867744
Catalog Number:
1000279-69-5
CAS Number:
1000279-69-5
Description:
A-867744 is a positive allosteric modulator of α7 nAChRs (IC50 values are 0.98 and 1.12 μM for human and rat α7 receptor ACh-evoked currents respectively, in X. laevis oocytes). Displays no activity at 5-HT3A, α3β4 or α4β2 nAChRs.
Molecular Weight:
402.89
Molecular Formula:
C20H19ClN2O3S
COA:
Inquire
MSDS:
Inquire
Targets:
nAChR
Chemical Structure
CAS 1000279-69-5 A-867744

Related nAChR Products


CP-601932
(CAS: 357425-68-4)

CP-601932 is a CNS-penetrant, high affinity, and selective α(4) β(2) nicotinic acetylcholine receptors partial agonist.

CAS 249296-44-4 Varenicline

Varenicline
(CAS: 249296-44-4)

Varenicline(CP 526555; Champix; Chantix) is a prescription medication used to treat smoking addiction. As a partial agonist it both reduces cravings for and dec...

CAS 220662-95-3 RJR-2403 oxalate

RJR-2403 oxalate
(CAS: 220662-95-3)

A neuronal nicotinic receptor agonist, showing high selectivity for the α4β2 subtype (Ki values are 26 and 36000 nM for α4β2 and α7 receptors respectively). Act...

CAS 2468-21-5 Catharanthine

Catharanthine
(CAS: 2468-21-5)

Catharanthine inhibits nicotinic receptor mediated diaphragm contractions with IC50 of 59.6 μM.

Nelonicline
(CAS: 1026134-63-3)

Nelonicline is an Alpha7 nicotinic acetylcholine receptor(nAChR) agonist and Nicotinic acetylcholine receptor agonist. It plays a key role in inflammatory proce...

Bradanicline
(CAS: 639489-84-2)

Bradanicline acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studie...

CP-810123
(CAS: 439608-12-5)

CP-810123 is a novel alpha 7 nAChR agonist with potential treatment for cognitive deficits associated with psychiatric or neurological conditions including schi...

Facinicline
(CAS: 677306-35-3)

Facinicline is a partial agonist of the nicotinic alpha-7 (α7) receptor. It is used for the oral treatment of Alzheimer's. It was being co-developed by Roche an...

CAS 156223-05-1 GTS-21

GTS-21
(CAS: 156223-05-1)

GTS-21, also known as DMBX-A, is a derivative of the natural product anabaseine that acts as a partial agonist at neural nicotinic acetylcholine receptors. It b...

CAS 541-22-0 Decamethonium Bromide

Decamethonium Bromide
(CAS: 541-22-0)

Decamethonium Bromide is a nicotinic AChR partial agonist and neuromuscular blocking agent.

A-366833
(CAS: 370882-41-0)

A-366833 is a an agonist at neural nicotinic acetylcholine receptors selective for the α4β2 subtype.

CAS 501925-31-1 PNU-120596

PNU-120596
(CAS: 501925-31-1)

PNU-120596 is a positive allosteric modulator of α7 nAChR with EC50 of 216 nM.

CAS 1000279-69-5 A-867744

A-867744
(CAS: 1000279-69-5)

A-867744 is a positive allosteric modulator of α7 nAChRs (IC50 values are 0.98 and 1.12 μM for human and rat α7 receptor ACh-evoked currents respectively, in X....

CAS 52-62-0 Pentolinium Tartrate

Pentolinium Tartrate
(CAS: 52-62-0)

Pentolonium tartrate is the tartrate salt form of pentolinium, which is a ganglionic blocking agent and acts as a nicotinic acetylcholine receptor antagonist. I...

CP-601927
(CAS: 357425-02-6)

CP-601927 is a CNS-penetrant, high affinity, and selective nicotinic acetylcholine receptor (nAChR) agonist.

CAS 7187-66-8 Trimethaphan

Trimethaphan
(CAS: 7187-66-8)

Trimetaphan camsilate can counteract cholinergic transmission at the ganglion type of nicotinic receptors of the autonomic ganglia and this lead to block both t...

CAS 50700-72-6 Vecuronium Bromide

Vecuronium Bromide
(CAS: 50700-72-6)

Vecuronium bromide (Norcuron) is a muscle relaxant in the category of non-depolarizing blocking agents. Vecuronium bromide is indicated as an adjunct to general...

CAS 123464-89-1 PNU-282987

PNU-282987
(CAS: 123464-89-1)

Highly selective α7 nAChR agonist (Ki = 26 nM) displaying negligible blockade of α1β1γδ and α3β4 nAChRs (IC50 ≥ 60 μM). Found to be inactive against a panel of ...

AZD 0328
(CAS: 220099-91-2)

AZD 0328 is a potent α7 NNR/5HT3 receptor agonist. AZD0328 led to a significant increase in cortical dopamine release in awake rodents and improved both conditi...

CAS 96946-42-8 Cisatracurium besylate

Cisatracurium besylate
(CAS: 96946-42-8)

Cisatracurium besylate is a neuromuscular blocking agent that is used in liver transplant patient with safety. Cisatracurium besylate is also an enantiomer of A...

Reference Reading


1.Discovery of 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744) as a novel positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor.
Faghih R1, Gopalakrishnan SM, Gronlien JH, Malysz J, Briggs CA, Wetterstrand C, Ween H, Curtis MP, Sarris KA, Gfesser GA, El-Kouhen R, Robb HM, Radek RJ, Marsh KC, Bunnelle WH, Gopalakrishnan M. J Med Chem. 2009 May 28;52(10):3377-84. doi: 10.1021/jm9003818.
The discovery of a series of pyrrole-sulfonamides as positive allosteric modulators (PAM) of alpha7 nAChRs is described. Optimization of this series led to the identification of 19 (A-867744), a novel type II PAM with good potency and selectivity. Compound 19 showed acceptable pharmacokinetic profile across species and brain levels sufficient to modulate alpha7 nAChRs. In a rodent model of sensory gating, 19 normalized gating deficits. These results suggest that 19 represents a novel class of molecules capable of allosteric modulation of the alpha7 nAChRs.
2.In vitro pharmacological characterization of a novel allosteric modulator of alpha 7 neuronal acetylcholine receptor, 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744), exhibiting unique pharmacological profile.
Malysz J1, Grønlien JH, Anderson DJ, Håkerud M, Thorin-Hagene K, Ween H, Wetterstrand C, Briggs CA, Faghih R, Bunnelle WH, Gopalakrishnan M. J Pharmacol Exp Ther. 2009 Jul;330(1):257-67. doi: 10.1124/jpet.109.151886. Epub 2009 Apr 23.
Targeting alpha7 neuronal acetylcholine receptors (nAChRs) with selective agonists and positive allosteric modulators (PAMs) is considered a therapeutic approach for managing cognitive deficits in schizophrenia and Alzheimer's disease. In this study, we describe a novel type II alpha7 PAM, 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744), that exhibits a unique pharmacological profile. In oocytes expressing alpha7 nAChRs, A-867744 potentiated acetylcholine (ACh)-evoked currents, with an EC(50) value of approximately 1 microM. At highest concentrations of A-867744 tested, ACh-evoked currents were essentially nondecaying. At lower concentrations, no evidence of a distinct secondary component was evident in contrast to 4-naphthalen-1-yl-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonic acid amide (TQS), another type II alpha7 PAM. In the presence of A-867744, ACh concentration responses were potentiated by increases in potency, Hill slope, and maximal efficacy.